PET/CT radiomics in breast cancer: promising tool for prediction of pathological response to neoadjuvant chemotherapy
Lidija Antunovic(Humanitas University), Martina Sollini(Humanitas University), Rita De Sanctis(Humanitas University), Renata Zelić(Karolinska University Hospital), Luca Cozzi(IRCCS Humanitas Research Hospital), Margarita Kirienko(Humanitas University), Corrado Tinterri(Humanitas University), Arturo Chiti(Vita-Salute San Raffaele University), Andrea Sagona(IRCCS Humanitas Research Hospital), Armando Santoro(IRCCS Humanitas Research Hospital), Rosalba Torrisi(IRCCS Humanitas Research Hospital)
Cited by 150
Related Papers
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
|Journal of Hepatology|2012|821
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743
Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib
|JAMA|2014|569
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study
|The Lancet Oncology|2012|550
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
|New England Journal of Medicine|2021|532